LFWD Quote, Financials, Valuation and Earnings

GlucoTrack has a net margin of -96.03% compared to Lifeward's net margin of --. Lifeward's return on equity of -92.59% beat GlucoTrack's return on equity of --.

Lifeward has a consensus price target of $8.67, signalling upside risk potential of 1071.17%. On the other hand GlucoTrack has an analysts' consensus of -- which suggests that it could fall by --. Given that Lifeward has higher upside potential than GlucoTrack, analysts believe Lifeward is more attractive than GlucoTrack.

Lifeward has a beta of 0.016, which suggesting that the stock is 98.425% less volatile than S&P 500. In comparison GlucoTrack has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.622%.

Lifeward has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward pays -- of its earnings as a dividend. GlucoTrack pays out -- of its earnings as a dividend.

Lifeward quarterly revenues are $5M, which are larger than GlucoTrack quarterly revenues of --. Lifeward's net income of -$4.8M is higher than GlucoTrack's net income of -$6.8M. Notably, Lifeward's price-to-earnings ratio is -- while GlucoTrack's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward is 0.27x versus 6.23x for GlucoTrack. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -96.03% compared to Lifeward's net margin of --. Lifeward's return on equity of -92.59% beat Plus Therapeutics's return on equity of --.

Lifeward has a consensus price target of $8.67, signalling upside risk potential of 1071.17%. On the other hand Plus Therapeutics has an analysts' consensus of $9.17 which suggests that it could grow by 2729.22%. Given that Plus Therapeutics has higher upside potential than Lifeward, analysts believe Plus Therapeutics is more attractive than Lifeward.

Lifeward has a beta of 0.016, which suggesting that the stock is 98.425% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.722%.

Lifeward has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Lifeward quarterly revenues are $5M, which are larger than Plus Therapeutics quarterly revenues of --. Lifeward's net income of -$4.8M is higher than Plus Therapeutics's net income of -$17.4M. Notably, Lifeward's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward is 0.27x versus 0.53x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -96.03% compared to Lifeward's net margin of -2201.34%. Lifeward's return on equity of -92.59% beat VolitionRX's return on equity of --.

Lifeward has a consensus price target of $8.67, signalling upside risk potential of 1071.17%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that Lifeward has higher upside potential than VolitionRX, analysts believe Lifeward is more attractive than VolitionRX.

Lifeward has a beta of 0.016, which suggesting that the stock is 98.425% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Lifeward has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Lifeward quarterly revenues are $5M, which are larger than VolitionRX quarterly revenues of $246.4K. Lifeward's net income of -$4.8M is higher than VolitionRX's net income of -$5.4M. Notably, Lifeward's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward is 0.27x versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -96.03% compared to Lifeward's net margin of 0.18%. Lifeward's return on equity of -92.59% beat Xtant Medical Holdings's return on equity of -26.62%.

Lifeward has a consensus price target of $8.67, signalling upside risk potential of 1071.17%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Lifeward has higher upside potential than Xtant Medical Holdings, analysts believe Lifeward is more attractive than Xtant Medical Holdings.

Lifeward has a beta of 0.016, which suggesting that the stock is 98.425% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Lifeward has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifeward pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Lifeward quarterly revenues are $5M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Lifeward's net income of -$4.8M is lower than Xtant Medical Holdings's net income of $58K. Notably, Lifeward's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifeward is 0.27x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.